Clinical Trial Update: Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

The Phase 3 trial evaluating MBP8298 for secondary progressive multiple sclerosis has been terminated; the update discusses efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Secondary Progressive

Drugs mentioned

• MBP8298

Snippet

Sponsor: BioMS Technology Corp. | Conditions: Multiple Sclerosis, Secondary Progressive | Phase 3 | Status: TERMINATED